Morphogen pathways in systemic sclerosis

Current Rheumatology Reports

Volumn 15, Issue 1, 2013, Pages

  Beyer, Christian ^a   Distler, Jörg H W ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

Fibrosis; Hedgehog; Morphogen; Notch; Pathways; Scleroderma; Systemic sclerosis; Wnt

Indexed keywords

ADENOVIRUS VECTOR; AXIN; BETA CATENIN; COLLAGEN; DICKKOPF 1 PROTEIN; ENZYME INHIBITOR; GAMMA SECRETASE INHIBITOR; ICG 001; LDE 223; MORPHOGEN; NOTCH RECEPTOR; PKF 310118; PROTEIN INHIBITOR; SEMAGACESTAT; SONIC HEDGEHOG PROTEIN; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 1; UNCLASSIFIED DRUG; VISMODEGIB; WNT PROTEIN; XAV 939;

AGEUSIA; ALZHEIMER DISEASE; ARTICLE; CELL ACTIVATION; CLINICAL TRIAL (TOPIC); DISEASE EXACERBATION; DRUG PROTEIN BINDING; EXPERIMENTAL MODEL; FIBROBLAST; HAIR LOSS; HUMAN; MUSCLE CRAMP; NEUROTOXICITY; NONHUMAN; PROTEIN BINDING; PROTEIN PROTEIN INTERACTION; PROTEIN SYNTHESIS INHIBITION; SIGNAL TRANSDUCTION; SKIN FIBROSIS; SYSTEMIC SCLEROSIS; VIRAL GENE DELIVERY SYSTEM;

EID: 84870466553     PISSN: 15233774     EISSN: 15346307     Source Type: Journal    
DOI: 10.1007/s11926-012-0299-6     Document Type: Article

References (50)

1. Varga J, Abraham D. Systemic sclerosis: a prototypic multisystem fibrotic disorder. J Clin Invest. 2007;117(3):557-67. (Pubitemid 46348510)
2. Gabrielli A, Avvedimento EV, Krieg T. Scleroderma. N Engl J Med. 2009;360(19):1989-2003.
3. Steen VD, Medsger TA. Changes in causes of death in systemic sclerosis, 1972-2002. Ann Rheum Dis. 2007;66(7):940-4. (Pubitemid 46999798)
4. Beyer C, Distler O, Distler JH. Innovative antifibrotic therapies in systemic sclerosis. Curr Opin Rheumatol. 2012;24(3):274-80.
5. Beyer C, Distler JH. The scientific basis for novel treatments of systemic sclerosis. F1000 Med Rep. 2009;1:95.
6. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100(1):57-70. (Pubitemid 30046295)
7. Nusse R, Varmus H. Three decades of Wnts: a personal perspective on how a scientific field developed. EMBO J. 2012;31 (12):2670-84.
8. Jiang J, Struhl G. Regulation of the Hedgehog and Wingless signalling pathways by the F-box/WD40-repeat protein Slimb. Nature. 1998;391(6666):493-6. (Pubitemid 28086550)
9. Maniatis T. A ubiquitin ligase complex essential for the NFkappaB, Wnt/Wingless, and Hedgehog signaling pathways. Genes Dev. 1999;13(5):505-10. (Pubitemid 29131874)
10. Yang L, Lin C, Liu ZR. P68 RNA helicase mediates PDGFinduced epithelial mesenchymal transition by displacing Axin from beta-catenin. Cell. 2006;127(1):139-55. (Pubitemid 44466634)
11. Valenta T, Hausmann G, Basler K. The many faces and functions of beta-catenin. EMBO J. 2012;31(12):2714-36.
12. Akhmetshina A, Palumbo K, Dees C, et al. Activation of canonical Wnt signalling is required for TGF-beta-mediated fibrosis. Nat Commun. 2012;3:735.
13. He W, Dai C, Li Y, et al. Wnt/beta-catenin signaling promotes renal interstitial fibrosis. J Am Soc Nephrol. 2009;20(4):765-76.
14. Konigshoff M, Kramer M, Balsara N, et al. WNT1-inducible signaling protein-1 mediates pulmonary fibrosis in mice and is upregulated in humans with idiopathic pulmonary fibrosis. J Clin Invest. 2009;119(4):772-87.
15. Kobayashi K, Luo M, Zhang Y, et al. Secreted Frizzled-related protein 2 is a procollagen C proteinase enhancer with a role in fibrosis associated with myocardial infarction. Nat Cell Biol. 2009;11(1):46-55.
16. Beyer C, Schramm A, Akhmetshina A, et al. beta-catenin is a central mediator of pro-fibrotic Wnt signaling in systemic sclerosis. Ann Rheum Dis. 2012;71(5):761-7.
17. Lam AP, Flozak AS, Russell S, et al. Nuclear beta-catenin is increased in systemic sclerosis pulmonary fibrosis and promotes lung fibroblast migration and proliferation. Am J Respir Cell Mol Biol. 2011;45(5):915-22.
18. Wei J, Melichian D, Komura K, et al. Canonical Wnt signaling induces skin fibrosis and subcutaneous lipoatrophy: a novel mouse model for scleroderma? Arthritis Rheum. 2011;63(6):1707-17.
19. Wei J, Fang F, Lam AP, et al. Wnt/beta-catenin signaling is hyperactivated in systemic sclerosis and induces Smad-dependent fibrotic responses in mesenchymal cells. Arthritis Rheum. 2012.
20. Bayle J, Fitch J, Jacobsen K, et al. Increased expression of Wnt2 and SFRP4 in Tsk mouse skin: role of Wnt signaling in altered dermal fibrillin deposition and systemic sclerosis. J Invest Dermatol. 2008;128(4):871-81. (Pubitemid 351374297)
21. Bergmann C, Akhmetshina A, Dees C, et al. Inhibition of glycogen synthase kinase 3beta induces dermal fibrosis by activation of the canonical Wnt pathway. Ann Rheum Dis. 2011;70 (12):2191-8.
22. Longo KA, Wright WS, Kang S, et al. Wnt10b inhibits development of white and brown adipose tissues. J Biol Chem. 2004;279 (34):35503-9. (Pubitemid 39100550)
23. Polakis P. Drugging Wnt signalling in cancer. EMBO J. 2012;31 (12):2737-46.
24. Simons BD, Clevers H. Strategies for homeostatic stem cell selfrenewal in adult tissues. Cell. 2011;145(6):851-62.
25. Chen B, Dodge ME, Tang W, et al. Small molecule-mediated disruption of Wnt-dependent signaling in tissue regeneration and cancer. Nat Chem Biol. 2009;5(2):100-7.
26. Fujii N, You L, Xu Z, et al. An antagonist of dishevelled protein- protein interaction suppresses beta-catenin-dependent tumor cell growth. Cancer Res. 2007;67(2):573-9. (Pubitemid 46192194)
27. Huang SM, Mishina YM, Liu S, et al. Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling. Nature. 2009;461 (7264):614-20.
28. Lepourcelet M, Chen YN, France DS, et al. Small-molecule antagonists of the oncogenic Tcf/beta-catenin protein complex. Cancer Cell. 2004;5(1):91-102. (Pubitemid 38121599)
29. Hao S, He W, Li Y, et al. Targeted Inhibition of {beta}-Catenin/ CBP Signaling Ameliorates Renal Interstitial Fibrosis. J Am Soc Nephrol. 2011.
30. Henderson Jr WR, Chi EY, Ye X, et al. Inhibition of Wnt/betacatenin/ CREB binding protein (CBP) signaling reverses pulmonary fibrosis. Proc Natl Acad Sci U S A. 2010;107(32):14309-14.
31. Distler A, Deloch L, Huang J, et al. Inactivation of tankyrases inhibits canonical Wnt signaling and reduces experimental fibrosis. Ann Rheum Dis. 2011;submitted.
32. Beyer C, Schramm A, Akan H, et al. Blockade of canonical Wnt signaling inhibits experimental dermal fibrosis. Ann Rheum Dis. 2012;submitted.
33. Ingham PW, Nakano Y, Seger C. Mechanisms and functions of Hedgehog signalling across the metazoa. Nat Rev Genet. 2011;12 (6):393-406.
34. Gallet A. Hedgehog morphogen: from secretion to reception. Trends Cell Biol. 2011;21(4):238-46.
35. Horn A, Palumbo K, Cordazzo C, et al. Hedgehog signaling controls fibroblast activation and tissue fibrosis in systemic sclerosis. Arthritis Rheum. 2012.
36. Horn A, Kireva T, Palumbo-Zerr K, et al. Inhibition of hedgehog signalling prevents experimental fibrosis and induces regression of established fibrosis. Ann Rheum Dis. 2012;71(5):785-9.
37. Choi SS, Omenetti A, Syn WK, Diehl AM. The role of Hedgehog signaling in fibrogenic liver repair. Int J Biochem Cell Biol. 2011;43(2):238-44.
38. Zerr P, Palumbo-Zerr K, Akhmetshina A, et al. Inhibition of hedgehog signaling for the treatment of murine sclerodermatous chronic graft-versus-host disease. Blood. 2012;120(14):2909-17.
39. Lear JT. Oral hedgehog-pathway inhibitors for basal-cell carcinoma. N Engl J Med. 2012;366(23):2225-6.
40. Fortini ME. Notch signaling: the core pathway and its posttranslational regulation. Dev Cell. 2009;16(5):633-47.
41. Andersson ER, Sandberg R, Lendahl U. Notch signaling: simplicity in design, versatility in function. Development. 2011;138 (17):3593-612.
42. Dees C, Tomcik M, Zerr P, et al. Notch signalling regulates fibroblast activation and collagen release in systemic sclerosis. Ann Rheum Dis. 2011;70(7):1304-10.
43. Kavian N, Servettaz A, Mongaret C, et al. Targeting ADAM-17/ notch signaling abrogates the development of systemic sclerosis in a murine model. Arthritis Rheum. 2010;62(11):3477-87.
44. Dees C, Zerr P, Tomcik M, et al. Inhibition of Notch signaling prevents experimental fibrosis and induces regression of established fibrosis. Arthritis Rheum. 2011;63(5):1396-404.
45. Sirin Y, Susztak K. Notch in the kidney: development and disease. J Pathol. 2012;226(2):394-403.
46. Axelrod JD, Matsuno K, Artavanis-Tsakonas S, Perrimon N. Interaction between Wingless and Notch signaling pathways mediated by dishevelled. Science. 1996;271(5257):1826-32.
47. Blokzijl A, Dahlqvist C, Reissmann E, et al. Cross-talk between the Notch and TGF-beta signaling pathways mediated by interaction of the Notch intracellular domain with Smad3. J Cell Biol. 2003;163(4):723-8. (Pubitemid 37517880)
48. Dahlqvist C, Blokzijl A, Chapman G, et al. Functional Notch signaling is required for BMP4-induced inhibition of myogenic differentiation. Development. 2003;130(24):6089-99. (Pubitemid 38008810)
49. Itoh F, Itoh S, Goumans MJ, et al. Synergy and antagonism between Notch and BMP receptor signaling pathways in endothelial cells. EMBO J. 2004;23(3):541-51. (Pubitemid 38282386)
50. Imbimbo BP, Giardina GA. gamma-secretase inhibitors and modulators for the treatment of Alzheimer's disease: disappointments and hopes. Curr Top Med Chem. 2011;11(12):1555-70.